AJMC December 28, 2024
The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.
These articles reflect growing trends of biosimilar development and their potential impacts on health care costs and patient access.
Here are the top 5 most-read biosimilar articles in 2024.
5. FDA Approves Imuldosa, a Fifth Biosimilar to Stelara
The FDA has approved Imuldosa, a biosimilar to Stelara, for treating autoimmune diseases like plaque psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis. Stelara, a top-selling biologic, generated over $10 billion globally in 2023. Imuldosa was jointly developed by Dong-A ST and Meiji Seika Pharma. This is Dong-A ST’s second FDA approval, following Sivextro in 2014, and 1...
Today's Sponsors
Today's Sponsor